Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
By Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for
Earnings season marches on as investors will hear from big companies including McDonald's and CoreWeave. Data on the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.